No Data
US Stock MarketDetailed Quotes
ALDX Aldeyra Therapeutics
Watchlist
3.160
-0.080-2.47% Close 12/08 16:00 ET
3.249+0.089+2.81%
Post 19:42 ET
3.340High3.150Low792.88KVolume
3.220Open3.240Pre Close2.55MTurnover1.73%Turnover RatioLossP/E (TTM)185.88MMarket Cap11.97052wk HighLossP/E (Static)58.82MShares1.42052wk Low1.51P/B144.72MFloat Cap16.700Historical High--Dividend TTM45.80MShs Float1.420Historical Low--Div YieldTTM5.86%Amplitude3.215Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Aldeyra Therapeutics Company
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
News
Optimistic Outlook for Aldeyra Therapeutics Despite FDA Setback: A Strong Buy Rating
FDA Rejects Aldeyra Therapeutics' Dry Eye Disease Candidate, Asks For Additional Study
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) New Drug Application (NDA) of reproxalap, an investigational drug candidate for dry eye disease. Although no safe
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and ClearPoint Neuro (CLPT)
Comments
$Aldeyra Therapeutics(ALDX.US$
A very cheap and promising company with a market value of over 10 billion.
A very cheap and promising company with a market value of over 10 billion.
$Aldeyra Therapeutics(ALDX.US$ If you missed the game stop, then this stock must not be missed. The surge will happen again. It will be able to significantly increase the company's profit returns and reflect the company's true value. Don't miss this rocket. Time will tell everything.
1
1
$Aldeyra Therapeutics(ALDX.US$ Nowadays, people often look at computers, phones, and pad screens, which increases the burden on their eyes and has become popular. The company's drugs can help people reduce the burden of damage to their eyes through global sales, greatly increasing the company's value and reaching a market value of 10 billion in the near future. , take novo company as an example, the current market value of this company is very cheap. There is no reason not to invest in this c...
2
LMAO!
$Aldeyra Therapeutics(ALDX.US$ KING NY LIFE BLOCKED ME! hehehe! He/She bad mouthed me and told me to get out because im a alarmist! hehehe! tried to respond with facts that im a day trader and i do just fine! but im blocked now and didnt get the chance to respond! OH WHAT AM I TO DO NOW? ALL THE SLEEP I WILL MIS BECAUSE OF THIS! OH I KNOW, ILL COUNT THE PROFIT I MAKE FROM TRADING SMART AND NOT EMOTIONAL! hehehe! But i also dont slam someone and then block them because im just to sensitive!...
10
$Aldeyra Therapeutics(ALDX.US$ JMO! but if not tonight? Tomorrow this thing will crater! In my opinion this will be lucky if it only loses 50%
1
Yuk!
$Aldeyra Therapeutics(ALDX.US$ said Monday it has received a letter from the US Food and Drug Administration stating that its
new drug application for reproxalap, a drug candidate for the treatment of dry eye disease, did not demonstrate efficacy.
The FDA also told Aldeyra that "at least one additional adequate and well-controlled study" should be conducted, the company said.
Aldeyra said it expects to resubmit the NDA in the first half of 2024, pending the FDA's feedback on the Special Pro...
new drug application for reproxalap, a drug candidate for the treatment of dry eye disease, did not demonstrate efficacy.
The FDA also told Aldeyra that "at least one additional adequate and well-controlled study" should be conducted, the company said.
Aldeyra said it expects to resubmit the NDA in the first half of 2024, pending the FDA's feedback on the Special Pro...
5
Grrrr
$Aldeyra Therapeutics(ALDX.US$ Aldeyra Therapeutics Receives Complete Response Letter From FDA; Says Additional Trial Required To Demonstrate Positive Effect On The Treatment Of Ocular Symptoms In Dry Eye Disease
FDA PDUFA
$Aldeyra Therapeutics(ALDX.US$ Should find out if FDA gives approval for REPROXALAP? It was on FDA calendar for 11/23/23? Remember i posted on I believe 11/1 about the exclusive licensing agreement that will also come if approval is granted? I believe i have to in anticipation of this give ! Hehehe
! Hehehe 4
$Aldeyra Therapeutics(ALDX.US$ anything can happen in 3 more days holding 🙏🚀
1
$Aldeyra Therapeutics(ALDX.US$ 5 days chart looks good , i am in ⤴️🎯
$Aldeyra Therapeutics(ALDX.US$ I imagine shorts are bringing this down? 8 hours ago there was 1.7 M share LTB now there is only 850K LTB
1
Update
$Aldeyra Therapeutics(ALDX.US$ Aldeyra Will Receive A Option Fee Of $1M And Upfront Payment Of $100M Less Option Fees If AbbVie Chooses To Exercise; Would Be Eligible To Receive Up To $300M In Regulatory And Commercial Milestone Payments, Inclusive Of A $100M Paymeent Upon FDA Approval
4
News
$Aldeyra Therapeutics(ALDX.US$ Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--